# Epitalon Dosage in Research: Doses, Routes, and Half-Life > Epitalon dosage as studied in research: rodent and in-vitro doses, routes, the cycled-administration pattern, and the unmeasured half-life. No human dosing. The doses and routes used in published studies, the cycled-administration pattern, and why no human pharmacokinetic half-life exists. ## Before the details This page describes Epitalon dosage only as it appears in published research — what was given, to which species, by which route, in which study. It is not a protocol, and it contains no recommendation for any person. In short: the rodent lifespan work used roughly a microgram per mouse, injected under the skin, for five days a month rather than every day; cell studies used concentrations in the microgram-per-milliliter range; and the human studies used parenteral courses over short cycles. No one has measured how long Epitalon lasts in a human bloodstream, so the often-repeated "a few minutes" figure is an educated guess from peptide chemistry, not a number from an Epitalon study. Wherever you see a dose below, read it as "this is what a study did," never as "this is what to take." ## Epitalon dosage Epitalon dosage in the research record means the doses used in animal and cell studies. The most-cited rodent regimen comes from the SHR-mouse lifespan study: `1.0 ug/mouse` subcutaneously (roughly `30-40 ug/kg`), given five consecutive days per month from three months of age [3]. Lower-dose rodent carcinogenesis schedules used `0.1 ug/mouse` subcutaneously, and a rat colon-carcinogenesis model used a `1 ug` subcutaneous course [12]. In vitro, the 2025 human cell-line telomere studies used `0.1-1 ug/mL` in the culture medium [8]; the original human-fibroblast telomerase work added the peptide to culture medium at a concentration the abstract did not specify [1]. The shared feature across the rodent work is intermittent, cycled dosing rather than continuous exposure. ## Routes studied Subcutaneous injection is the predominant route in both the rodent and the reported human work [3]. Cell and oocyte studies add the peptide directly to culture medium [8]. One rat study delivered the peptide intranasally to examine neocortex neuron activity, and the Russian clinical and observational studies used parenteral courses over 10-20 day cycles [2]. The route table on this page, drawn from the studies, pairs each route with the model it was used in; none of it describes administration to a person outside a research setting. ## Epitalon half life No formal pharmacokinetic half-life study has been published for Epitalon in humans. As an unmodified linear tetrapeptide, it is expected to undergo rapid proteolytic degradation in plasma, consistent with short-peptide half-lives that are generally measured in minutes — but this is an inference from peptide chemistry, not a measured Epitalon value [4]. The practical consequence researchers cite for the short presumed half-life is that any systemic effect would be brief, which is part of the rationale offered for the cycled dosing pattern. Until a human pharmacokinetic study is run, the Epitalon half life should be treated as unknown rather than as the "few minutes" figure that circulates. ## Why researchers cycle rather than dose continuously The rodent studies consistently used short monthly courses — five days on, the rest of the month off — rather than daily administration [3]. The stated reasoning combines the presumed short half-life with the geroprotector framing, in which periodic pulses are proposed to normalize an age-related axis rather than to maintain a continuous blood level. This cycled pattern is a feature of the study designs; it is not a dosing instruction, and the published record does not establish an optimal interval for any species, let alone for humans. ## Handling and stability in research practice In research handling, lyophilized peptide is typically stored at `-20 C`; reconstituted solution in bacteriostatic water is refrigerated at `2-8 C` and used within a few weeks, since repeated freeze-thaw cycling degrades short peptides. These are general research-handling conventions, not manufacturer directions or clinical guidance. No human clinical dosing exists to standardize against: no Phase II/III randomized placebo-controlled trial for Epitalon is registered, and the published human courses used Russian parenteral schedules that differ from FDA/EMA reporting standards [2]. --- A brushed-steel reference on the Epitalon record — the telomerase and melatonin findings logged to source, and the single Russian research lineage behind them stated as plainly as the claims themselves; no clinic behind the console and nothing here dosed, sourced, prescribed, or sold.